


The Great Imitator: reverse testing algorithm in focus

1936



Kamran Kadkhoda, Ph.D, FCCM, D(ABMM), D(ABMLI)

Clinical Microbiologist, Cadham Provincial Public Health Laboratory

Assistant Professor, Dept. Medical Microbiology & Infectious Diseases; Dept. Immunology, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba

- Syphilis has been known for centuries as the “**Great imitator**” → caused by a spirochete: *Treponema pallidum ssp. pallidum*
- **Transmission** typically happens during primary and secondary syphilis from **highly infectious lesions** (ID₅₀: **57 organisms**)
- **Congenital transmission**: 1) trans-placentally; 2) during vaginal delivery
- Through blood transfusion and C/T/O transplantation: both **rare in developed countries**
- **Syphilis paves the way for contracting HIV**: behaviourally and biologically (**like canary in the coal mine for HIV**)

- **WHO estimates in 2008:** 11 million incident cases and 36 million prevalent cases of venereal syphilis globally
 - ~1.36 million of them estimated to be **pregnant**
- **Mainly in developing countries** especially in sub-saharan Africa, SE Asia, as well as Eastern Europe, Russia, and China
- Huge drop in incident syphilis cases in 1940s after **the introduction of penicillin** with small peaks every decade

- **Drastic rise** in incident syphilis cases during 2000-2010 especially **among MSM**:
 - *i)* risky sexual behaviour
 - *ii)* on-line dating
 - *iii)* HIV sero-sorting
 - *iv)* Availability of HAART and HIV PrEP misconception
 - *v)* condom fatigue
- Similar trend in Canada with **481% rise** during 2000- 2012 from 1.84 to 8.85/100,000 population
- **Incidence**: 2016 in MB: **21 per 100,000** (RPR-pos)
- Increased male-to-female **ratio**
- Early prenatal screening and Rx → **Decreased** the number of **congenital syphilis** cases though with small fluctuations in North America




Figure 1) Reported overall and sex-specific rates of infectious syphilis in Canada, 1993 to 2012 (9) CPHLN Syphilis task group; CJIDMM, Jan-Feb 2015

PHAC Data; 2008




Figure 12: Reported Rates of Infectious Syphilis in Males by Age Group, 1999 to 2008, Canada






Figure 13: Reported Rates of Infectious Syphilis in Females by Age Group, 1999 to 2008, Canada

PHAC Data; 2008




of patinets screened for Syphilis in MB



Manual testing not quite feasible with such high and increasing numbers

51% rise in numbers since 2000 !


of newly diagnosed syphilis cases of all stages at CPL since 2010 (77% rise)





Laboratory Dx

- **Direct detection:**
 - *In vivo* propagation
 - Microscopy
 - PCR
- **Serological detection:**
 - Traditional (conventional) algorithm
 - **Reverse-sequence algorithm**

- **Isolation** not feasible routinely and axenically
- **Rabbit Infectivity Test**: Gold Standard but costly, lengthy, technically-demanding
- Direct detection can be performed by **dark-field microscopy** (DF) or **Direct fluorescence assay** (DFA)
 - Both are rather obsolete with poor performance characteristics
 - Technically demanding
 - Hard to obtain reagents
- Discontinued @ CPL in 2011



Dark-field microscopy (DF)



Specimen should be examined within **20 minutes** as **motility** has to be seen

Almost completely obsolete

LOD: 10^4 - 10^5 spirochetes/ml

PCR using specific primers (*bmp*, *tpp47*, *poIA*) is highly sensitive and specific; **available through CPL** (→ **NML**)

Flocked-, Dacron-, Rayon-tipped swabs in VTM on cold packs → sent to CPL preferably on the same day

AMERICAN SOCIETY FOR MICROBIOLOGY | Journal of Clinical Microbiology

HOME | CURRENT ISSUE | ARCHIVE | ALERTS | ABOUT ASM | CONTACT US | TECH SUPPORT | Journals.ASM.org

Tonsillar Syphilis^{*} an unusual site of infection diagnosed by *Treponema pallidum* PCR

John R. M. Smith¹, Raymond S. W. Tsang² and Kamran Kadkhoda^{3,4,5} ↑

+ Author Affiliations

ABSTRACT

With the re-emergence of syphilis, it is important that both clinical and public health practitioners recognize the various clinical manifestations of this disease (formerly known as “the great imitator”) and become familiar with the newer diagnostic tests. Here we report the first case of tonsillar syphilis diagnosed by PCR.

This Article

Accepted manuscript posted online 15 July 2015, doi: 10.1128/JCM.01634-15
JCM.01634-15

- » Abstract PDF
- Article Usage Stats
- Services

Article Usage Statistics

Email this article to a colleague
Similar articles in ASM journals
Alert me when this article is cited
Alert me if a correction is posted
Similar articles in this journal
Similar articles in PubMed
Alert me to new issues of JCM


Serology: the mainstay of syphilis diagnosis

- **Treponemal tests** (e.g., **TP-PA**, FTA-ABS, EIA, CMIA)
 - **Specific** antibodies
 - Typically appear within **2-3 weeks after infection**
 - **Remain positive for life** in ca. 85% of healthy subjects
 - Not affected by treatment
 - Not affected by “**biological false positivity**” phenomenon
- If the screen test starts with Treponemal tests, the algorithm is called: “**reverse-sequence algorithm**”

FROM manual RPR TO walk-away, automated, random-access Syphilis screening



Antibody patterns during treponemal infection²




Examples of
Treponemal tests



Treponema pallidum – Particle Agglutination

- It is **relatively labour-intensive** and time-consuming
- Takes up to 3 hours as opposed to 30 minutes on the automated/random-access platforms



The old version using RBCs: **MHA-TP**

- Using sheep RBCs
- Now obsolete

FTA-ABS USED TO BE CALLED “REFERENCE”?

CDC Home



Centers for Disease Control and Prevention
CDC 24/7: Saving Lives. Protecting People.™

MMWR

All CDC Topics

Choose a topic above

SEARCH

A-Z Index [A](#) [B](#) [C](#) [D](#) [E](#) [F](#) [G](#) [H](#) [I](#) [J](#) [K](#) [L](#) [M](#) [N](#) [O](#) [P](#) [Q](#) [R](#) [S](#) [T](#) [U](#) [V](#) [W](#) [X](#) [Y](#) [Z](#) <#>

Morbidity and Mortality Weekly Report (MMWR)

[MMWR](#)



[Recommend](#) [Tweet](#) [Share](#)

Discordant Results from Reverse Sequence Syphilis Screening --- Five Laboratories, United States, 2006--2010

Weekly

February 11, 2011 / 60(05);133-137


Traditionally, the FTA-ABS test has been considered the gold standard treponemal test and still is used by some laboratories. However, the FTA-ABS test has lower specificity than other treponemal tests and probably lower sensitivity (9). In addition to inherent subjectivity, the FTA-ABS test also requires trained personnel and a dedicated fluorescence microscope. For these reasons, CDC recommends that the FTA-ABS test not be used to confirm discordant treponemal screening results. Based on published sensitivity and specificity data, the TP-PA test currently is considered to be the most suitable confirmatory treponemal test (10).

Discontinued at CPL but it is still done on CSF samples at NML

Syphilis Immunoblot: as a confirmatory test

- Still labour-intensive
- Not-approved by Health Canada

Streptavidin
Level 3+
Level 1+
Level +/-
TpN47
TpN17
TpN15
TnpA



Current CMI test used at CPL uses:

- Takes only 30 min
- Walk-away system

3 recombinant antigens
from *Treponema pallidum*:

TpN 15

TpN 17

TpN 47

CMI specificity: **99.85%**

Serology cannot differentiate
venereal syphilis from
endemic treponematoses




An example of a random-access
automated platform
(currently used @ CPL)

What is CMIA?


What is **CMIA** anyways? **C**ash **M**anagement **I**mprovement **A**ct? Or? **C**hemiluminescent **M**icroparticle **I**mmuno**a**ssay


Principle of the test



¹, *E. coli*-expressed recombinant antigens: **TpN 15**; **TpN 17**; **TpN 47**


- **Screening with a non-treponemal test (RPR)** → and if reactive, then followed by a treponemal test (e.g., TP-PA)
- **RPR**: Rapid Plasma Reagin
- **VDRL**: Venereal Disease Research Laboratory
- **Antigens**: Cholesterol, Cardiolipin, Lecithin
- Based on **Flocculation (Wassermann test)**: as opposed to agglutination
- Flocculation is based on the presence of **lipoidal antigens** in liquid phase
- RPR/VDRL look for “**Reagin**” antibody (misnomer)






RPR: Macroscopic

VDRL: Microscopic



RPR is used to screen **CMIA** positive samples → if Reactive → **VDRL** to determine the end titre

Advantages of reverse-sequence testing algorithm

- Very **early detection** of treponemal infection (treponemal antibodies appear earlier than non-treponemal ones)
- Higher **sensitivity** during latent and late syphilis
- **Less labour and cost** for the laboratory especially with random access platforms
- Improved **turnaround time**
- Less detection of **biological false positives** 
- **BFPs**: Acute vs. Chronic:
($<$ or $>$ 6 months duration)


Infectious Diseases

- Lyme disease*
- Leptospirosis
- Relapsing fever
- Ratbite fever (*Spirillum minus*)
- Leprosy
- Tuberculosis
- Pneumococcal pneumonia
- Subacute bacterial endocarditis
- Chancroid
- Scarlet fever
- Rickettsial disease
- Malaria
- Trypanosomiasis
- Mycoplasma pneumoniae*
- Chickenpox
- Lymphogranuloma venereum
- Hepatitis (especially hepatitis C) *
- Infectious mononucleosis

Noninfectious Diseases

- Drug addiction
- Any connective tissue disease disorder
- Rheumatoid heart disease
- Blood transfusions (multiple)
- Pregnancy
- "Old age"
- any vaccination
- Chronic liver disease (noninfectious)

An example of a syphilis reverse sequence algorithm



TP-PA is done for specimens with **no previous positive Hx** of Syphilis to check for CMIA false positive results

How to request syphilis testing?



Cadham Provincial Laboratory General Requisition



ONLY ONE SPECIMEN TYPE PER REQUISITION

All areas of the requisition must be completed (please print clearly)
See back for requisition/specimen instructions

Cadham Provincial Laboratory
P.O. Box 8450
750 William Avenue
Winnipeg, MB R3C 3Y1

Tel: (204) 945-6123
Fax: (204) 786-4770
E-mail: cadham@gov.mb.ca
Website: www.gov.mb.ca/health/publichealth/cpl



SEROLOGY					
Serology Test Panels (see #1 over)					
<input type="checkbox"/> STI Panel				<input type="checkbox"/> Prenatal Panel	
<input type="checkbox"/> Post Exposure: Source Panel (1, 3)				<input type="checkbox"/> Prenatal HIV OPT OUT (2)	
<input type="checkbox"/> Post Exposure: Exposed Panel (1)				<input type="checkbox"/> Blood-borne Pathogen	
HIV (4)	<input type="checkbox"/> HIV1/2Ab			<input type="checkbox"/> Syphilis Screen	
Hepatitis					
<input type="checkbox"/> HAV IgG (Immunity)				<input type="checkbox"/> HBsAb (Immunity)	
<input type="checkbox"/> HAV IgM (acute HAV)				<input type="checkbox"/> HBsAg	
<input type="checkbox"/> HBcAb (Total)				<input type="checkbox"/> HCV Ab	
Nucleic Acid (Plasma Only) (5)					
<input type="checkbox"/> HBV PCR/Quant	<input type="checkbox"/> HCV PCR/Quant			<input type="checkbox"/> WNV PCR	
<input type="checkbox"/> HCV PCR/Qual	<input type="checkbox"/> HCV Genotyping				
Miscellaneous Serology					
	Acute	Immune Status		Acute	Immune Status
CMV	<input type="checkbox"/> IgM	<input type="checkbox"/> IgG	Parvo B19	<input type="checkbox"/> IgM	<input type="checkbox"/> IgG
EBV	<input type="checkbox"/> IgM	<input type="checkbox"/> IgG	Rubella	<input type="checkbox"/> IgM	<input type="checkbox"/> IgG
HSV	<input type="checkbox"/> IgM	<input type="checkbox"/> IgG	Toxoplasma	<input type="checkbox"/> IgM	<input type="checkbox"/> IgG
Measles	<input type="checkbox"/> IgM	<input type="checkbox"/> IgG	Varicella	<input type="checkbox"/> IgM	<input type="checkbox"/> IgG
Mumps	<input type="checkbox"/> IgM	<input type="checkbox"/> IgG	WNV	<input type="checkbox"/> IgM	
<input type="checkbox"/> Lyme Ab	<input type="checkbox"/> H. pylori Ab		<input type="checkbox"/> Mycoplasma pneumoniae IgM		

How to interpret Syphilis results

Examples of True and False positive CMI A results

Final Syphilis Interpretation

1

The results suggest either recent or previous Treponemal infection.

Treponema pallidum antibody (CMIA)

Positive

Reagin antibody (VDRL)

Reactive

1:64 dilution, 64 dil.

Treponema pallidum antibody (Aggl)

Reactive

TP-PA

Final Syphilis Interpretation

2

Indeterminate Syphilis results. This result suggests very recent infection or a non-specific reaction. Repeat testing should be considered after 7 - 10 days if clinically indicated.

Treponema pallidum antibody (CMIA)

Positive

Reagin antibody (RPR)

Non-Reactive

Treponema pallidum antibody (Aggl)

Non-reactive

TP-PA

Final Syphilis Interpretation

3

Indeterminate. Combined with previous test results, these findings suggest a non-specific screening test result.

Treponema pallidum antibody (CMIA)

Positive

Reagin antibody (RPR)

Non-Reactive

CPHLN LABORATORY GUIDELINES

Canadian Public Health Laboratory Network laboratory guidelines for the use of serological tests (excluding point-of-care tests) for the diagnosis of syphilis in Canada

Paul N Levett DSc (D)ABMM FCCM FAAM¹, Kevin Fonseca PhD D(ABMM)², Raymond SW Tsang PhD³, Kamran Kadkhoda PhD FCCM^{4,5}, Bouchra Serhir MSc PhD⁶, Sandra M Radons BSc⁷, Muhammad Morshed PhD SCCM^{8,9*}

CPHLN LABORATORY GUIDELINES

Canadian Public Health Laboratory Network laboratory guidelines for the use of direct tests to detect syphilis in Canada

Raymond SW Tsang PhD^{1*}, Muhammad Morshed PhD SCCM^{2,3}, Max A Chernesky PhD FIDSA FAAM FCCM⁴, Gayatri C Jayaraman PhD MPH⁵, Kamran Kadkhoda PhD FCCM^{6,7}

CPHLN LABORATORY GUIDELINES

Canadian Public Health Laboratory Network laboratory guidelines for congenital syphilis and syphilis screening in pregnant women in Canada

Ameeta E Singh BMBS MSc FRCPC^{1*}, Paul N Levett DSc (D)ABMM FCCM FAAM^{2*}, Kevin Fonseca PhD D(ABMM)³, Gayatri C Jayaraman MPH PhD⁴, Bonita E Lee MD FRCPC MSc⁵



Home > Infectious Diseases > Sexual Health and Sexually Transmitted Infections > Canadian Guidelines on Sexually Transmitted Infections > Canadian Guidelines on Sexually Transmitted Infections > Section 5 - Management and Treatment of Specific Infections - Syphilis

Main Menu

[About the Agency](#)

[Infectious Diseases](#)

[Chronic Diseases](#)

+/- TEXT PRINT SHARE

Canadian Guidelines on Sexually Transmitted Infections

Table 6. Monitoring of serologic tests and other follow up

Primary, secondary, early latent	, 3, 6, 12 months after treatment
Late latent, tertiary (EXCEPT NEUROSYPHILIS)	12 and 24 months after treatment

Table 7. Adequate serologic response

Primary	4-fold drop at 6 months; 8-fold drop at 12 months; 16-fold drop at 24 months
Secondary	8-fold drop at 6 months and 16 fold drop at 12 months
Early latent	4-fold drop at 12 months

**Thanks for your
attention**

Office #: (204)945-7545

email:

kamran.kadkhoda@gov.mb.ca